Menu
Home Explore People Places Arts History Plants & Animals Science Life & Culture Technology
On this page
Iron supplement
Iron formulation used to prevent or treat iron deficiency anemia

Iron supplements, also known as iron salts and iron pills, are a number of iron formulations used to treat and prevent iron deficiency including iron-deficiency anemia. For prevention they are only recommended in those with poor absorption, heavy menstrual periods, pregnancy, hemodialysis, or a diet low in iron. Prevention may also be used in low birth weight babies. They are taken by mouth, injection into a vein, or injection into a muscle. While benefits may be seen in days, up to two months may be required until iron levels return to normal.

Common side effects include constipation, abdominal pain, dark stools, and diarrhea. Other side effects, which may occur with excessive use, include iron overload and iron toxicity. Ferrous salts used as supplements by mouth include ferrous fumarate, ferrous gluconate, ferrous succinate, and ferrous sulfate. Injectable forms include iron dextran and iron sucrose. They work by providing the iron needed for making red blood cells.

Iron pills have been used medically since at least 1681, with an easy-to-use formulation being created in 1832 using chicken liver extracts and the majority from plants. Ferrous salt is on the World Health Organization's List of Essential Medicines. Ferrous salts are available as a generic medication and over the counter. Slow release formulations, while available, are not recommended. In 2021, ferrous sulfate was the 105th most commonly prescribed medication in the United States, with more than 6 million prescriptions.

Related Image Collections Add Image
Profiles
1 Image
We don't have any YouTube videos related to Iron supplement yet.
We don't have any PDF documents related to Iron supplement yet.
We don't have any Books related to Iron supplement yet.
We don't have any archived web articles related to Iron supplement yet.

Medical uses

Iron supplements are used to treat or prevent iron deficiency and iron-deficiency anemia;20 parenteral irons can also be used to treat functional iron deficiency, where requirements for iron are greater than the body's ability to supply iron such as in inflammatory states. The main criterion is that other causes of anemia have also been investigated, such as vitamin B12 or folate deficiency, drug induced or due to other poisons such as lead, as often the anemia has more than one underlying cause.21

Iron deficiency anemia is classically a microcytic, hypochromic anemia. Generally, in the UK oral preparations are trialled before using parenteral delivery,22 unless there is a requirement for a rapid response, previous intolerance to oral iron, or likely failure to respond. Intravenous iron may decrease the need for blood transfusions however it increases the risk of infections when compared to oral iron.23 Daily oral supplementation of iron during pregnancy reduces the risk of maternal anemia, and the effects on infant and other maternal outcomes are not clear.24 Another review found tentative evidence that intermittent iron supplements by mouth for mothers and babies are similar to daily supplementation with fewer side effects.25 Supplements by mouth should be taken on an empty stomach, optionally with a small amount of food to reduce discomfort.26

Athletes

Athletes may be at elevated risk of iron deficiency and so benefit from supplementation, but the circumstances vary between individuals, and dosage should be based on tested ferritin levels, since in some cases supplementation may be harmful.27

Frequent blood donors

Main article: Blood donation

Frequent blood donors may be advised to take iron supplements. Canadian Blood Services recommends discussing "taking iron supplements with your doctor or pharmacist" as "the amount of iron in most multivitamins may not meet your needs and iron supplements may be necessary".28 The American Red Cross recommends "taking a multivitamin with 18 mg of iron or an iron supplement with 18-38 mg of elemental iron for 60 days after each blood donation, for 120 days after each power red donation or after frequent platelet donations".29 A 2014 Cochrane Review found that blood donors were less likely to be deferred for low hemoglobin levels if they were taking oral iron supplements, although 29% of those who took them experienced side effects in contrast to the 17% that took a placebo. It is unknown what the long-term effects of iron supplementation for blood donors may be.30

Side effects

Side effects of therapy with oral iron include diarrhea, constipation, or epigastric abdominal discomfort. Taken after a meal, side effects decrease, but there is an increased risk of interaction with other substances. Side effects are dose-dependent, and the dose may be adjusted.

The patient may notice that their stools become black. This is completely harmless, but patients must be warned about this to avoid unnecessary concern. When iron supplements are given in a liquid form, teeth may reversibly discolor (this can be avoided through the use of a straw). Intramuscular injection can be painful, and brown discoloration may be noticed.

Treatments with iron(II) sulfate have higher incidence of adverse events than iron(III)-hydroxide polymaltose complex (IPC)313233 or iron bis-glycinate chelate.3435

Iron overdose has been one of the leading causes of death caused by toxicological agents in children younger than six years.36

Iron poisoning may result in mortality or short-term and long-term morbidity.37

Infection risk

Because one of the functions of elevated ferritin (an acute phase reaction protein) in acute infections is thought to be to sequester iron from bacteria, it is generally thought that iron supplementation (which circumvents this mechanism) should be avoided in patients who have active bacterial infections. Replacement of iron stores is seldom such an emergency that it cannot wait for any such acute infection to be treated.

Some studies have found that iron supplementation can lead to an increase in infectious disease morbidity in areas where bacterial infections are common. For example, children receiving iron-enriched foods have demonstrated an increased rate in diarrhea overall and enteropathogen shedding. Iron deficiency protects against infection by creating an unfavorable environment for bacterial growth. Nevertheless, while iron deficiency might lessen infections by certain pathogenic diseases, it also leads to a reduction in resistance to other strains of viral or bacterial infections, such as Salmonella typhimurium or Entamoeba histolytica. Overall, it is sometimes difficult to decide whether iron supplementation will be beneficial or harmful to an individual in an environment that is prone to many infectious diseases; however this is a different question than the question of supplementation in individuals who are already ill with a bacterial infection.38

Children living in areas prone to malaria infections are also at risk of developing anemia. It was thought that iron supplementation given to such children could increase the risk of malaria infection in them. A Cochrane systematic review published in 2016 found high-quality evidence that iron supplementation does not increase the risk of clinical malaria in children.39

Contraindications

Contraindications often depend on the substance in question. Documented hypersensitivity to any ingredients and anemias without proper work-up (i.e., documentation of iron deficiency) is true of all preparations. Some can be used in iron deficiency, others require iron deficiency anaemia to be present. Some are also contraindicated in rheumatoid arthritis.40

Hemochromatosis

Individuals may be genetically predisposed to excessive iron absorption, as is the case with those with HFE hereditary hemochromatosis. Within the general population, 1 out of 400 people has the homozygous form of this genetic trait, and 1 out of every 10 people has its heterozygous form.41 Neither individuals with the homozygous nor heterozygous form should take iron supplements.42

Interactions

Non-heme iron forms an insoluble complex with several other drugs, resulting in decreased absorption of both iron and the other drug. Examples include tetracycline, penicillamine, methyldopa, levodopa, bisphosphonates, and quinolones. The same can occur with elements in food, such as calcium, which impacts both heme and non-heme iron absorption.43 Absorption of iron is better at a low pH (i.e. an acidic environment), and absorption is decreased if there is a simultaneous intake of antacids.

Many other substances decrease the rate of non-heme iron absorption. One example is tannins from foods such as tea44 and phytic acid.45 Because iron from plant sources is less easily absorbed than the heme-bound iron of animal sources, vegetarians and vegans should have a somewhat higher total daily iron intake than those who eat meat, fish or poultry.4647

Taken after a meal, there are fewer side effects, but there is also less absorption because of interaction and pH alteration. Generally, an interval of 2–3 hours between the iron intake and that of other drugs seems advisable, but is less convenient for patients and can impact compliance.

History

The first pills were commonly known as Blaud's pills,48 which were named after P. Blaud of Beaucaire, the French physician who introduced and started the use of these medications as a treatment for patients with anemia.49

Administration

By mouth

"Proferrin" redirects here. For the pupil dilator, see Prefrin.

Iron can be supplemented by mouth using various forms, such as iron(II) sulfate. This is the most common and well-studied soluble iron salt sold under brand names such as Feratab, Fer-Iron, and Slow-FE. It is in complex with gluconate, dextran, carbonyl iron, and other salts. Ascorbic acid, vitamin C, increases the absorption of non-heme sources of iron, but not to a clinically significant degree.50

Heme iron polypeptide (HIP) (e.g., Proferrin ES and Proferrin Forte) can be used when regular iron supplements such as ferrous sulfate or ferrous fumarate are not tolerated or absorbed. A clinical study demonstrated that HIP increased serum iron levels 23 times greater than ferrous fumarate on a milligram-per-milligram basis.51

Another alternative is ferrous glycine sulfate or ferroglycine sulfate, which has fewer gastrointestinal side effects than standard preparations such as iron fumarate.52 [better source needed] It is unusual among oral preparations of iron supplements in that the iron in this preparation has very high oral bioavailability, especially in the liquid formulation. This option should be evaluated before resorting to parenteral therapy. It is especially useful in iron deficiency anemia associated with autoimmune gastritis and Helicobacter pylori gastritis, where it generally has a satisfactory effect.53

Since iron stores in the body are generally depleted, and there is a limit to what the body can process (about 2–6 mg/kg of body mass per day; i.e. for a 100 kg/220 lb man this is equal to a maximum dose of 200–600 mg/per day) without iron poisoning, this is a chronic therapy which may take 3–6 months.54

Due to the frequent intolerance of oral iron and the slow improvement, parenteral iron is recommended in many indications.5556

Food fortification

Fortified foods with iron such as breakfast cereals and wheat flour are effective in increasing hemoglobin levels and lowering prevalence of anemia and iron deficiency.575859 A 2021 Cochrane Review found that wheat flour fortified with iron may reduce anemia by 27%.60 Fortified rice may increase haemoglobin concentrations and reduce iron deficiency in the general population but has not been found to reduce anemia.61 In 2023, the World Health Organization recommended fortification of rice with iron as a public health strategy to improve the iron status of populations in regions where rice is a staple food.62

By injection

Iron therapy (intravenously or intramuscular) is given when therapy by mouth has failed (not tolerated), oral absorption is seriously compromised (by illnesses, or when the person cannot swallow), benefit from oral therapy cannot be expected, or fast improvement is required (for example, prior to elective surgery).63 Parenteral therapy is more expensive than oral iron preparations and is not suitable during the first trimester of pregnancy.64

There are cases where parenteral iron is preferable over oral iron. These are cases where oral iron is not tolerated, where the haemoglobin needs to be increased quickly (e.g. post partum, post operatively, post transfusion), where there is an underlying inflammatory condition (e.g. inflammatory bowel disease) or renal patients, the benefits of parenteral iron far outweigh the risks.

Low-certainty evidence suggests that IBD-related anemia treatment with Intravenous (IV) iron infusion may be more effective than oral iron therapy, with fewer people needing to stop treatment early due to adverse effects.65 The type of iron preparation may be an important determinant of clinical benefit. Moderate-certainty evidence suggests response to treatment may be higher when IV ferric carboxymaltose, rather than IV iron sucrose preparation is used, despite very-low certainty evidence of increased adverse effects, including bleeding, in those receiving ferric carboxymaltose treatment.66

In many cases, use of intravenous iron such as ferric carboxymaltose has lower risks of adverse events than a blood transfusion and as long as the person is stable is a better alternative.67 Ultimately this always remains a clinical decision based on local guidelines, although National Guidelines are increasingly stipulating IV iron in certain groups of patients.6869

A Cochrane review of controlled trials comparing intravenous (IV) iron therapy with oral iron supplements in people with chronic kidney disease, found low-certainty evidence that people receiving IV-iron treatment were 1.71 times as likely to reach their target hemoglobin levels.70 Overall, hemoglobin was 0.71g/dl higher than those treated with oral iron supplements. Iron stores in the liver, estimated by serum ferritin, were also 224.84 μg/L higher in those receiving IV-iron.71 However, there was also low-certainty evidence that allergic reactions were more likely following IV-iron therapy. It was unclear whether the type of iron therapy administration affects the risk of death from any cause, including cardiovascular, or whether it may alter the number of people who may require a blood transfusion or dialysis.72

Soluble iron salts have a significant risk of adverse effects and can cause toxicity due to damage to cellular macromolecules. Delivering iron parenterally has utilised various molecules to limit this. This has included dextrans, sucrose, carboxymaltose, and Isomaltoside 1000.

One formulation of parenteral iron is iron dextran which covers the old high molecular weight (brand name Dexferrum) and the much safer low molecular iron dextrans (brand names including Cosmofer and Infed).73

Iron sucrose has an occurrence of allergic reactions of less than 1 in 1000.74 A common side effect is taste changes, especially a metallic taste, occurring in between 1 in 10 and 1 in 100 treated patients.75 It has a maximum dose of 200 mg on each occasion according to the SPC, but it has been given in doses of 500 mg. Doses can be given up to 3 times a week.76

Iron carboxymaltose is marketed as Ferinject,77 Injectafer,7879 and Iroprem in various countries.80 The most common side effects are headaches which occur in 3.3%, and hypophosphatemia, which occurs in more than 35%.8182

Iron isomaltoside 1000 (brand name Monofer) is a formulation of parenteral iron that has a matrix structure that results in very low levels of free iron and labile iron. It can be given at high doses – 20 mg/kg in a single visit – with no upper dose limit. This formulation has the benefit of giving a full iron correction in a single visit.8384

Ferric maltol, marketed as Accrufer85 and Ferracru, is available in oral and intravenous preparations. When used as a treatment for IBD-related anemia, very low certainty evidence suggests a marked benefit with oral ferric maltol compared with placebo. However, it was unclear whether the IV preparation was more effective than oral ferric maltol.86

References

  1. Hamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 217. ISBN 9781284057560. 9781284057560 ↩

  2. British National Formulary: BNF 69 (69 ed.). British Medical Association. 2015. pp. 660–664. ISBN 9780857111562. 9780857111562 ↩

  3. British National Formulary: BNF 69 (69 ed.). British Medical Association. 2015. pp. 660–664. ISBN 9780857111562. 9780857111562 ↩

  4. World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 247–250. hdl:10665/44053. ISBN 9789241547659. 9789241547659 ↩

  5. British National Formulary: BNF 69 (69 ed.). British Medical Association. 2015. pp. 660–664. ISBN 9780857111562. 9780857111562 ↩

  6. British National Formulary: BNF 69 (69 ed.). British Medical Association. 2015. pp. 660–664. ISBN 9780857111562. 9780857111562 ↩

  7. "Iron Preparations, Oral". The American Society of Health-System Pharmacists. Archived from the original on 22 May 2016. Retrieved 8 January 2017. https://www.drugs.com/monograph/iron-preparations-oral.html ↩

  8. "Iron Preparations, Oral". The American Society of Health-System Pharmacists. Archived from the original on 22 May 2016. Retrieved 8 January 2017. https://www.drugs.com/monograph/iron-preparations-oral.html ↩

  9. Hamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 217. ISBN 9781284057560. 9781284057560 ↩

  10. World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 247–250. hdl:10665/44053. ISBN 9789241547659. 9789241547659 ↩

  11. World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 247–250. hdl:10665/44053. ISBN 9789241547659. 9789241547659 ↩

  12. World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 247–250. hdl:10665/44053. ISBN 9789241547659. 9789241547659 ↩

  13. "Iron Preparations, Oral". The American Society of Health-System Pharmacists. Archived from the original on 22 May 2016. Retrieved 8 January 2017. https://www.drugs.com/monograph/iron-preparations-oral.html ↩

  14. Upfal J (2006). Australian Drug Guide. Black Inc. pp. 378–379. ISBN 9781863951746. Archived from the original on 18 September 2017. 9781863951746 ↩

  15. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO. /wiki/World_Health_Organization ↩

  16. Hamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 217. ISBN 9781284057560. 9781284057560 ↩

  17. British National Formulary: BNF 69 (69 ed.). British Medical Association. 2015. pp. 660–664. ISBN 9780857111562. 9780857111562 ↩

  18. "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024. https://clincalc.com/DrugStats/Top300Drugs.aspx ↩

  19. "Ferrous Sulfate - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024. https://clincalc.com/DrugStats/Drugs/FerrousSulfate ↩

  20. "Ferinject 50 mg iron/mL dispersion for injection/infusion". emc. https://www.medicines.org.uk/emc/product/5910 ↩

  21. "Ferric carboxymaltose". Farbe Firma Pvt Ltd. 28 June 2023. It consists of a complex of ferric iron (Fe3+) and carboxymaltose, a carbohydrate molecule. It is a colloidal solution. https://www.farbefirma.org/post/the-iron-battle ↩

  22. Goddard AF, James MW, McIntyre AS, Scott BB, et al. (British Society of Gastroenterology) (October 2011). "Guidelines for the management of iron deficiency anaemia" (PDF). Gut. 60 (10): 1309–16. doi:10.1136/gut.2010.228874. PMID 21561874. S2CID 52804934. Archived from the original (PDF) on 22 April 2012. https://web.archive.org/web/20120422205151/http://www.bsg.org.uk/pdf_word_docs/iron_def.pdf ↩

  23. Litton E, Xiao J, Ho KM (August 2013). "Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials". BMJ. 347: f4822. doi:10.1136/bmj.f4822. PMC 3805480. PMID 23950195. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805480 ↩

  24. Finkelstein JL, Cuthbert A, Weeks J, Venkatramanan S, Larvie DY, De-Regil LM, et al. (15 August 2024). "Daily oral iron supplementation during pregnancy". The Cochrane Database of Systematic Reviews. 2024 (8): CD004736. doi:10.1002/14651858.CD004736.pub6. PMC 11325660. PMID 39145520. /wiki/Doi_(identifier) ↩

  25. Peña-Rosas JP, De-Regil LM, Gomez Malave H, Flores-Urrutia MC, Dowswell T (October 2015). "Intermittent oral iron supplementation during pregnancy". The Cochrane Database of Systematic Reviews. 2015 (10): CD009997. doi:10.1002/14651858.CD009997.pub2. PMC 7092533. PMID 26482110. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092533 ↩

  26. "Taking iron supplements". MedlinePlus Medical Encyclopedia. U.S. National Library of Medicine. Retrieved 11 August 2018. https://medlineplus.gov/ency/article/007478.htm ↩

  27. Clénin G, Cordes M, Huber A, Schumacher YO, Noack P, Scales J, et al. (2015). "Iron deficiency in sports - definition, influence on performance and therapy". Swiss Medical Weekly (Review). 145: w14196. doi:10.4414/smw.2015.14196. PMID 26512429. https://doi.org/10.4414%2Fsmw.2015.14196 ↩

  28. "What you need to know about iron". Canadian Blood Services. Retrieved 30 May 2022. https://www.blood.ca/en/blood/am-i-eligible/abcs-eligibility/iron ↩

  29. "Frequent Blood Donors and the Importance of Iron". American Red Cross Blood Services. Retrieved 30 May 2022. https://www.redcrossblood.org/donate-blood/blood-donation-process/before-during-after/iron-blood-donation/iron-informationforfrequentdonors.html ↩

  30. Smith GA, Fisher SA, Doree C, Di Angelantonio E, Roberts DJ (July 2014). "Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors". The Cochrane Database of Systematic Reviews (7): CD009532. doi:10.1002/14651858.CD009532.pub2. PMC 11019466. PMID 24990381. S2CID 205200473. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11019466 ↩

  31. Geisser P (2007). "Safety and efficacy of iron(III)-hydroxide polymaltose complex / a review of over 25 years experience". Arzneimittel-Forschung. 57 (6A): 439–452. doi:10.1055/s-0031-1296693. PMID 17691594. S2CID 70657238. /wiki/Doi_(identifier) ↩

  32. Toblli JE, Brignoli R (2007). "Iron(III)-hydroxide polymaltose complex in iron deficiency anemia / review and meta-analysis". Arzneimittel-Forschung. 57 (6A): 431–438. doi:10.1055/s-0031-1296692. PMID 17691593. S2CID 2635923. /wiki/Doi_(identifier) ↩

  33. Saha L, Pandhi P, Gopalan S, Malhotra S, Saha PK (January 2007). "Comparison of efficacy, tolerability, and cost of iron polymaltose complex with ferrous sulphate in the treatment of iron deficiency anemia in pregnant women". MedGenMed. 9 (1): 1. PMC 1924983. PMID 17435611. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1924983 ↩

  34. Szarfarc SC, de Cassana LM, Fujimori E, Guerra-Shinohara EM, de Oliveira IM (March 2001). "Relative effectiveness of iron bis-glycinate chelate (Ferrochel) and ferrous sulfate in the control of iron deficiency in pregnant women". Archivos Latinoamericanos de Nutricion. 51 (1 Suppl 1): 42–47. PMID 11688081. /wiki/PMID_(identifier) ↩

  35. Ashmead SD (March 2001). "The chemistry of ferrous bis-glycinate chelate". Archivos Latinoamericanos de Nutricion. 51 (1 Suppl 1): 7–12. PMID 11688084. /wiki/PMID_(identifier) ↩

  36. Iron Toxicity at eMedicine https://emedicine.medscape.com/article/815213-overview ↩

  37. "Toxicity, Iron (Overview)". Tripdatabase.com. Archived from the original on 8 March 2016. Retrieved 21 December 2012. https://web.archive.org/web/20160308211454/https://www.tripdatabase.com/doc/813847-Toxicity-Iron-Overview ↩

  38. Oppenheimer SJ (February 2001). "Iron and its relation to immunity and infectious disease". The Journal of Nutrition. 131 (2S–2): 616S – 635S. doi:10.1093/jn/131.2.616S. PMID 11160594. https://doi.org/10.1093%2Fjn%2F131.2.616S ↩

  39. Neuberger A, Okebe J, Yahav D, Paul M (February 2016). "Oral iron supplements for children in malaria-endemic areas". The Cochrane Database of Systematic Reviews. 2016 (2): CD006589. doi:10.1002/14651858.CD006589.pub4. PMC 4916933. PMID 26921618. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916933 ↩

  40. "Cosmofer – Summary of Product Characteristics (SPC)". eMC. Archived from the original on 26 April 2014. Retrieved 21 December 2012. https://web.archive.org/web/20140426215550/http://www.medicines.org.uk/emc/medicine/14139 ↩

  41. Nielsen P, Nachtigall D (October 1998). "Iron supplementation in athletes. Current recommendations". Sports Medicine. 26 (4): 207–216. doi:10.2165/00007256-199826040-00001. PMID 9820921. S2CID 25517866. /wiki/Doi_(identifier) ↩

  42. Nielsen P, Nachtigall D (October 1998). "Iron supplementation in athletes. Current recommendations". Sports Medicine. 26 (4): 207–216. doi:10.2165/00007256-199826040-00001. PMID 9820921. S2CID 25517866. /wiki/Doi_(identifier) ↩

  43. Zijp IM, Korver O, Tijburg LB (September 2000). "Effect of tea and other dietary factors on iron absorption". Critical Reviews in Food Science and Nutrition. 40 (5): 371–398. doi:10.1080/10408690091189194. PMID 11029010. S2CID 12423113. /wiki/Doi_(identifier) ↩

  44. Delimont NM, Haub MD, Lindshield BL (February 2017). "The Impact of Tannin Consumption on Iron Bioavailability and Status: A Narrative Review". Current Developments in Nutrition. 1 (2): 1–12. doi:10.3945/cdn.116.000042. PMC 5998341. PMID 29955693. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998341 ↩

  45. Reddy MB, Hurrell RF, Juillerat MA, Cook JD (February 1996). "The influence of different protein sources on phytate inhibition of nonheme-iron absorption in humans". The American Journal of Clinical Nutrition. 63 (2): 203–207. doi:10.1093/ajcn/63.2.203. PMID 8561061. https://doi.org/10.1093%2Fajcn%2F63.2.203 ↩

  46. Mangels R. "Iron in the vegan diet". The Vegetarian Resource Group. /wiki/Reed_Mangels ↩

  47. Henjum S, Groufh-Jacobsen S, Stea TH, Tonheim LE, Almendingen K (March 2021). "Iron Status of Vegans, Vegetarians and Pescatarians in Norway". Biomolecules. 11 (3): 454. doi:10.3390/biom11030454. PMC 8003004. PMID 33803700. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003004 ↩

  48. "Blaud's pill – Medical Definition". Merriam-Webster. Archived from the original on 19 February 2010. Retrieved 21 December 2012. https://web.archive.org/web/20100219015237/http://www.merriam-webster.com/medical/blaud%27s%20pill ↩

  49. Robinson, Victor, ed. (1939). "P. Blaud of Beaucaire, Blaud's Pills for Anemia, Iron pills, Iron". The Modern Home Physician, A New Encyclopedia of Medical Knowledge. WM. H. Wise & Company (New York)., p. 435. /wiki/The_Modern_Home_Physician,_A_New_Encyclopedia_of_Medical_Knowledge ↩

  50. Deng J, Ramelli L, Li PY, Eshaghpour A, Schuenemann GE, Crowther MA (2 November 2023). "Efficacy of Vitamin C with Iron Supplementation in Iron Deficiency Anemia Patients: A Systematic Review and Meta-Analysis". Blood. 142 (Supplement 1). American Society of Hematology: 1091–1091. doi:10.1182/blood-2023-174801. ISSN 0006-4971. https://doi.org/10.1182%2Fblood-2023-174801 ↩

  51. Seligman PA, Moore GM, Schleicher RB (2000). "Clinical studies of hip: An oral heme-iron product". Nutrition Research. 20 (9): 1279–86. doi:10.1016/s0271-5317(00)00215-3. S2CID 84515114. /wiki/Doi_(identifier) ↩

  52. Aronstam A, Aston DL (1982). "A comparative trial of a controlled-release iron tablet preparation ('Ferrocontin' Continus) and ferrous fumarate tablets". Pharmatherapeutica. 3 (4): 263–267. PMID 7146040. /wiki/PMID_(identifier) ↩

  53. Hershko C, Ianculovich M, Souroujon M (2007). "Decreased treatment failure rates following duodenal release ferrous glycine sulfate in iron deficiency anemia associated with autoimmune gastritis and Helicobacter pylori gastritis". Acta Haematologica. 118 (1): 19–26. doi:10.1159/000101701. PMID 17426393. S2CID 46720321. /wiki/Doi_(identifier) ↩

  54. "Iron Poisoning". Webmd.com. 27 September 2012. Archived from the original on 12 April 2012. Retrieved 21 December 2012. https://web.archive.org/web/20120412155245/http://www.webmd.com/a-to-z-guides/iron-poisoning ↩

  55. National Clinical Guideline Centre (2015). Anaemia Management in Chronic Kidney Disease. NICE Guideline, No. 8. London: Royal College of Physicians. PMID 26065064. Archived from the original on 18 September 2017. https://www.ncbi.nlm.nih.gov/books/NBK299242/ ↩

  56. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. (IBD Section of the British Society of Gastroenterology) (May 2011). "Guidelines for the management of inflammatory bowel disease in adults" (PDF). Gut. 60 (5): 571–607. doi:10.1136/gut.2010.224154. PMID 21464096. S2CID 8269837. Archived from the original (PDF) on 21 June 2013. Retrieved 8 August 2012. https://web.archive.org/web/20130621085124/http://chinesefms.com/doc/zhw/doc_zhw_xzzn/201104/P020110416418498436822.pdf ↩

  57. Gera T, Sachdev HS, Boy E (2012). "Effect of iron-fortified foods on hematologic and biological outcomes: systematic review of randomized controlled trials". Am J Clin Nutr. 96 (2): 309–324. doi:10.3945/ajcn.111.031500. PMID 22760566. https://www.sciencedirect.com/science/article/pii/S0002916523028915 ↩

  58. Helmyati S, Lusmilasari L, Sandhi A, Hardiyanti M, Rosilia G, Rachmawati YN, et al. (2025). "Systematic review on supplementation, fortification, and food-based interventions for preventing iron deficiency anemia in low- and middle-income countries". Asia Pac J Clin Nutr. 34 (1): 10–35. doi:10.6133/apjcn.202502_34(1).0002. PMC 11742596. PMID 39828255. https://pmc.ncbi.nlm.nih.gov/articles/PMC11742596/ ↩

  59. Dorbu AD, Waddel HB, Chadha MK, de Romaña DL, Arabi M, Moore RH, et al. (2025). "Nutritional Anemia Reductions Due to Food Fortification Among Women of Childbearing Age: A Literature Review and Bayesian Meta-Analysis". Matern Child Nutr: e13801. doi:10.1111/mcn.13801. PMID 39899434. https://onlinelibrary.wiley.com/doi/full/10.1111/mcn.13801 ↩

  60. Field MS, Mithra P, Peña-Rosas JP (2021). "Wheat flour fortification with iron and other micronutrients for reducing anaemia and improving iron status in populations". Cochrane Database Syst Rev. 1 (1): CD011302. doi:10.1002/14651858.CD011302.pub3. PMC 8407500. PMID 33461239. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011302.pub3/full ↩

  61. Peña-Rosas JP, Mithra P, Unnikrishnan B, Kumar N, De-Regil LM, Nair NS, et al. (2019). "Fortification of rice with vitamins and minerals for addressing micronutrient malnutrition". Cochrane Database Syst Rev. 2019 (10): CD009902. doi:10.1002/14651858.CD009902.pub2. PMC 6814158. PMID 31684687. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009902.pub2/full/hu ↩

  62. "Fortification of Rice". World Health Organization. 2023. Archived from the original on 15 April 2025. https://www.who.int/tools/elena/interventions/rice-fortification ↩

  63. Kumpf VJ (August 1996). "Parenteral iron supplementation". Nutrition in Clinical Practice. 11 (4): 139–146. doi:10.1177/0115426596011004139. PMID 9070014. /wiki/Doi_(identifier) ↩

  64. "Ferinject 50 mg iron/mL dispersion for injection/infusion". emc. https://www.medicines.org.uk/emc/product/5910 ↩

  65. Gordon M, Sinopoulou V, Iheozor-Ejiofor Z, Iqbal T, Allen P, Hoque S, et al. (January 2021). "Interventions for treating iron deficiency anaemia in inflammatory bowel disease". The Cochrane Database of Systematic Reviews. 1 (1): CD013529. doi:10.1002/14651858.CD013529.pub2. PMC 8092475. PMID 33471939. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092475 ↩

  66. Gordon M, Sinopoulou V, Iheozor-Ejiofor Z, Iqbal T, Allen P, Hoque S, et al. (January 2021). "Interventions for treating iron deficiency anaemia in inflammatory bowel disease". The Cochrane Database of Systematic Reviews. 1 (1): CD013529. doi:10.1002/14651858.CD013529.pub2. PMC 8092475. PMID 33471939. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092475 ↩

  67. Moore RA, Gaskell H, Rose P, Allan J (September 2011). "Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data". BMC Blood Disorders. 11: 4. doi:10.1186/1471-2326-11-4. PMC 3206450. PMID 21942989. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206450 ↩

  68. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. (July 2016). "2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC". European Heart Journal. 37 (27): 2129–2200. doi:10.1093/eurheartj/ehw128. PMID 27206819. https://doi.org/10.1093%2Feurheartj%2Fehw128 ↩

  69. Dignass AU, Gasche C, Bettenworth D, Birgegård G, Danese S, Gisbert JP, et al. (March 2015). "European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases". Journal of Crohn's & Colitis. 9 (3): 211–222. doi:10.1093/ecco-jcc/jju009. PMID 25518052. https://doi.org/10.1093%2Fecco-jcc%2Fjju009 ↩

  70. O'Lone EL, Hodson EM, Nistor I, Bolignano D, Webster AC, Craig JC, et al. (Cochrane Kidney and Transplant Group) (February 2019). "Parenteral versus oral iron therapy for adults and children with chronic kidney disease". The Cochrane Database of Systematic Reviews. 2019 (2): CD007857. doi:10.1002/14651858.CD007857.pub3. PMC 6384096. PMID 30790278. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384096 ↩

  71. O'Lone EL, Hodson EM, Nistor I, Bolignano D, Webster AC, Craig JC, et al. (Cochrane Kidney and Transplant Group) (February 2019). "Parenteral versus oral iron therapy for adults and children with chronic kidney disease". The Cochrane Database of Systematic Reviews. 2019 (2): CD007857. doi:10.1002/14651858.CD007857.pub3. PMC 6384096. PMID 30790278. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384096 ↩

  72. O'Lone EL, Hodson EM, Nistor I, Bolignano D, Webster AC, Craig JC, et al. (Cochrane Kidney and Transplant Group) (February 2019). "Parenteral versus oral iron therapy for adults and children with chronic kidney disease". The Cochrane Database of Systematic Reviews. 2019 (2): CD007857. doi:10.1002/14651858.CD007857.pub3. PMC 6384096. PMID 30790278. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384096 ↩

  73. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J (June 2004). "On the relative safety of parenteral iron formulations". Nephrology, Dialysis, Transplantation. 19 (6): 1571–1575. doi:10.1093/ndt/gfh185. PMID 15150356. /wiki/Doi_(identifier) ↩

  74. "Venofer". FASS (drug formulary) (in Swedish). Archived from the original on 1 October 2011. Allergiska reaktioner (inträffar hos färre än 1 av 1 000 patienter)" and "Vanliga (inträffar hos färre än 1 av 10 patienter): Tillfälliga smakförändringar (speciellt metallsmak). https://web.archive.org/web/20111001011331/http://www.fass.se/LIF/produktfakta/artikel_produkt.jsp?NplID=20000211000213&DocTypeID=7 ↩

  75. "Venofer". FASS (drug formulary) (in Swedish). Archived from the original on 1 October 2011. Allergiska reaktioner (inträffar hos färre än 1 av 1 000 patienter)" and "Vanliga (inträffar hos färre än 1 av 10 patienter): Tillfälliga smakförändringar (speciellt metallsmak). https://web.archive.org/web/20111001011331/http://www.fass.se/LIF/produktfakta/artikel_produkt.jsp?NplID=20000211000213&DocTypeID=7 ↩

  76. "Venofer (iron sucrose) - Summary of Product Characteristics (SmPC)". eMC. Archived from the original on 8 March 2017. Retrieved 7 March 2017. https://www.medicines.org.uk/emc/medicine/24168 ↩

  77. "Ferinject 50 mg iron/mL dispersion for injection/infusion". emc. https://www.medicines.org.uk/emc/product/5910 ↩

  78. "Injectafer- ferric carboxymaltose injection injection, solution; Injectafer- ferric carboxymaltose injection, solution". DailyMed. 1 May 2023. Retrieved 8 February 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=517b4a19-45b3-4286-9f6a-ced4e10447de ↩

  79. "Drug Approval Package: Injectafer (ferric carboxymaltose) Injection NDA #203565". U.S. Food and Drug Administration (FDA). 4 September 2013. Retrieved 8 February 2024.[dead link] https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203565Orig1s000TOC.cfm ↩

  80. Cançado RD, Muñoz M (2011). "Intravenous iron therapy: how far have we come?". Revista Brasileira de Hematologia e Hemoterapia. 33 (6): 461–469. doi:10.5581/1516-8484.20110123 (inactive 1 November 2024). PMC 3459360. PMID 23049364.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459360 ↩

  81. "Ferinject 50 mg iron/mL dispersion for injection/infusion". emc. https://www.medicines.org.uk/emc/product/5910 ↩

  82. "Injectafer- ferric carboxymaltose injection injection, solution; Injectafer- ferric carboxymaltose injection, solution". DailyMed. 1 May 2023. Retrieved 8 February 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=517b4a19-45b3-4286-9f6a-ced4e10447de ↩

  83. Jahn MR, Andreasen HB, Fütterer S, Nawroth T, Schünemann V, Kolb U, et al. (August 2011). "A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications". European Journal of Pharmaceutics and Biopharmaceutics. 78 (3): 480–491. doi:10.1016/j.ejpb.2011.03.016. PMID 21439379. /wiki/Doi_(identifier) ↩

  84. Cançado RD, Muñoz M (2011). "Intravenous iron therapy: how far have we come?". Revista Brasileira de Hematologia e Hemoterapia. 33 (6): 461–469. doi:10.5581/1516-8484.20110123 (inactive 1 November 2024). PMC 3459360. PMID 23049364.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459360 ↩

  85. "Drug Approval Package: Accrufer". U.S. Food and Drug Administration (FDA). 14 August 2019. Retrieved 8 February 2024. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212320Orig1s000TOC.cfm ↩

  86. Gordon M, Sinopoulou V, Iheozor-Ejiofor Z, Iqbal T, Allen P, Hoque S, et al. (January 2021). "Interventions for treating iron deficiency anaemia in inflammatory bowel disease". The Cochrane Database of Systematic Reviews. 1 (1): CD013529. doi:10.1002/14651858.CD013529.pub2. PMC 8092475. PMID 33471939. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092475 ↩